英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
3396查看　3396　在百度字典中的解释百度英翻中〔查看〕
3396查看　3396　在Google字典中的解释Google英翻中〔查看〕
3396查看　3396　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Halia Therapeutics - Halia - The Genetic Resilience Company
    At Halia Therapeutics, we shift the paradigm from treating illness to understanding resilience Using population-scale pedigrees and genetic data, we uncover protective factors that help some individuals resist disease - even with high-risk genotypes or environmental triggers
  • About - haliatx. com
    Halia Therapeutics, headquartered in Lehi, Utah, is dedicated to advancing therapies that meaningfully improve lives through science rooted in human biology ‍ The company was founded in 2017 after Dr John “Keoni” Kauwe identified a family with the high-risk APOE4 gene variant linked to Alzheimer’s, but none of them developed the disease His research uncovered a protective mutation
  • Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of . . .
    LEHI, Utah — June 3, 2025 — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of enrollment for its open-label Phase 2a clinical trial evaluating HT-6184 (Ofirnoflast) in patients with lower-risk Myelodysplastic Syndrome (MDS) who are refractory
  • Halia Therapeutics Pipeline
    Halia’s clinical team is led by scientists and doctors with deep expertise and experience in the design and execution of clinical trials to explore the activity of our product pipeline We have translated the compounds to demonstrate their activity in assays and in vivo models, which are readying them for clinical development
  • Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric . . .
    DLEHI, Utah, Nov 10, 2025 PRNewswire -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the 67 th American Society of Hematology (ASH) Annual Meeting Exposition taking place in Orlando, Florida, from
  • News Media | Halia Therapeutics
    Lee LandenbergerJanuary 31, 2024 Halia Therapeutics Inc has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead
  • Halia Therapeutics Strengthens Global Genomics Leadership with . . .
    Image caption goes here LEHI, Utah, Oct 6, 2025 PRNewswire -- Halia Therapeutics (The Genetic Resilience Company), a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced the appointment of Paul Jones as Chief Strategy Officer GM, International Markets
  • Halia Therapeutics Announces Presentation at the BIO Investment . . .
    Halia Therapeutics Announces Presentation at the BIO Investment Growth Summit LEHI, Utah — March 2, 2026—Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver acompany presentation at the BIO Investment Growth Summit
  • Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in . . .
    LEHI, Utah, Dec 8, 2025 PRNewswire -- Halia Therapeutics, a clinical-stage biopharmaceutical company, today presented new clinical data from its Phase 2a study of ofirnoflast (HT-6184) at the 67th American Society of Hematology (ASH) Annual Meeting
  • Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a . . .
    LEHI, Utah, June 16, 2025 PRNewswire -- Halia Therapeutics, Inc , a clinical-stage biopharmaceutical company redefining treatment paradigms through inflammation-targeted and resilience-driven therapies, today announced the successful completion of its first-in-human Phase 1 clinical trial evaluating HT-4253 in healthy adult volunteers





中文字典-英文字典  2005-2009